TECHNETIUM TC-99M PENTETATE KIT - Generic Drug Details

What are the generic drug sources for technetium tc-99m pentetate kit and what is the scope of patent protection?

Technetium tc-99m pentetate kit is the generic ingredient in four branded drugs marketed by Jubilant Draximage, Jubilant, and Ge Healthcare, and is included in four NDAs. Additional information is available in the individual branded drug profile pages.

One supplier is listed for this compound.

Summary for TECHNETIUM TC-99M PENTETATE KIT

US Patents:	0
Tradenames:	4
Applicants:	3
NDAs:	4
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	105
DailyMed Link:	TECHNETIUM TC-99M PENTETATE KIT at DailyMed

Pharmacology for TECHNETIUM TC-99M PENTETATE KIT

Drug Class	Lead Chelator
Mechanism of Action	Lead Chelating Activity

US Patents and Regulatory Information for TECHNETIUM TC-99M PENTETATE KIT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ge Healthcare	TECHNETIUM TC-99M PENTETATE KIT	technetium tc-99m pentetate kit	INJECTABLE;INJECTION	017264-002	Approved Prior to Jan 1, 1982		DISCN	No	No
Jubilant Draximage	AN-DTPA	technetium tc-99m pentetate kit	INJECTABLE;INJECTION	017714-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Ge Healthcare	MPI DTPA KIT - CHELATE	technetium tc-99m pentetate kit	INJECTABLE;INJECTION	017255-001	Approved Prior to Jan 1, 1982		DISCN	No	No

TECHNETIUM TC-99M PENTETATE KIT Market Analysis and Financial Projection Experimental

Technetium Tc-99m Pentetate Kit: Market Dynamics and Financial Trajectory

Introduction

Technetium Tc-99m Pentetate, a radiopharmaceutical used extensively in nuclear medicine, plays a crucial role in diagnostic imaging of various body organs. This article delves into the market dynamics and financial trajectory of the Technetium Tc-99m Pentetate Kit, highlighting its applications, market size, growth prospects, and challenges.

Applications and Uses

Technetium Tc-99m Pentetate is utilized in a wide range of diagnostic procedures, including kidney imaging, brain imaging, assessment of renal perfusion, and estimation of glomerular filtration rate. It is also used for lung ventilation studies to assess pulmonary embolic or obstructive airway disease[2][3].

Market Size and Growth

The global Technetium-99m market, which includes the Tc-99m Pentetate Kit, was valued at USD 4.95 billion in 2023. This market is projected to grow at a Compound Annual Growth Rate (CAGR) of 4.05% from 2024 to 2030, reaching approximately USD 6.54 billion by 2030[3].

Key Market Drivers

Several factors are driving the growth of the Technetium-99m market:

Increasing Demand for Diagnostic Procedures

The rising demand for diagnostic imaging procedures, particularly in cardiovascular, oncological, and neurological applications, is a significant driver. Technetium-99m is used in over 110,000 medical imaging procedures daily worldwide, with more than 40,000 of these procedures conducted in the United States alone[3].

Advancements in Radiopharmaceuticals

Ongoing research and development in creating new Tc-99m-based radiopharmaceuticals with improved specificity and sensitivity are enhancing diagnostic accuracy and driving market growth. These advancements enable more targeted imaging of various diseases, contributing to the increasing demand for Technetium-99m[3][4].

Expanding Healthcare Infrastructure

The development of healthcare infrastructure, especially in emerging markets like China, is increasing the demand for reliable and cost-effective diagnostic tools such as Tc-99m-based Single Photon Emission Computed Tomography (SPECT) imaging[3].

Market Segmentation

The Technetium-99m market is segmented based on various criteria:

By Application

• Cardiovascular Imaging: This segment held the largest market share in 2023, primarily due to its critical role in myocardial perfusion imaging.
• Bone Scans: Used for diagnosing bone-related disorders.
• Respiratory Imaging: Includes lung ventilation studies.
• Tumor Imaging: Used in oncological diagnostics.
• Others: Encompasses various other diagnostic applications[3].

By Isotopic Services

• Gamma Camera: Used for general nuclear medicine imaging.
• Single Photon Emission Computed Tomography (SPECT): A widely used technique for detailed imaging[3].

By End User

• Hospitals: Major consumers of Tc-99m-based radiopharmaceuticals.
• Diagnostic Centers: Increasingly using Tc-99m for various diagnostic procedures.
• Others: Includes research institutions and private clinics[3].

Regional Market Analysis

North America, led by the United States and Canada, holds a significant share of the global Technetium-99m market. This is attributed to the advanced healthcare infrastructure, high prevalence of chronic diseases, and substantial investments in medical imaging technology in these regions[3].

Financial Performance and Projections

The financial performance of the Technetium-99m market is robust, with a steady growth trajectory:

• Current Market Size: USD 4.95 billion in 2023.
• Projected Market Size: USD 6.54 billion by 2030.
• CAGR: 4.05% from 2024 to 2030[3].

Challenges and Regulatory Considerations

Despite the growth prospects, the market faces several challenges:

Regulatory Burden

The high cost involved in complying with regulatory standards, including detailed toxicity data and approved clinical studies, can hinder the commercial exploitation of new Tc-99m-based radiopharmaceuticals[4].

Supply Chain Issues

Ensuring a continuous and reliable supply of Technetium-99m is crucial, given its short half-life of 6 hours. Disruptions in the supply chain can impact market stability[3].

Conclusion

The Technetium Tc-99m Pentetate Kit is a vital component of the nuclear medicine landscape, with a strong market presence and growth potential. Driven by increasing demand for diagnostic procedures, advancements in radiopharmaceuticals, and expanding healthcare infrastructure, the market is expected to continue its upward trajectory.

Key Takeaways

• Market Size and Growth: The global Technetium-99m market was valued at USD 4.95 billion in 2023 and is expected to grow to USD 6.54 billion by 2030.
• Applications: Widely used in kidney imaging, brain imaging, renal perfusion assessment, and lung ventilation studies.
• Market Drivers: Increasing demand for diagnostic procedures, advancements in radiopharmaceuticals, and expanding healthcare infrastructure.
• Challenges: Regulatory burden and supply chain issues.

FAQs

Q1: What are the primary applications of Technetium Tc-99m Pentetate?

Technetium Tc-99m Pentetate is primarily used for kidney imaging, brain imaging, assessment of renal perfusion, and estimation of glomerular filtration rate. It is also used for lung ventilation studies[2][3].

Q2: What is the projected market size of the Technetium-99m market by 2030?

The Technetium-99m market is projected to reach approximately USD 6.54 billion by 2030[3].

Q3: What are the key drivers of the Technetium-99m market growth?

Key drivers include increasing demand for diagnostic procedures, advancements in radiopharmaceuticals, and the expansion of healthcare infrastructure in emerging markets[3].

Q4: Which region holds the largest share of the global Technetium-99m market?

North America, led by the United States and Canada, holds the largest share of the global Technetium-99m market[3].

Q5: What are the main challenges facing the Technetium-99m market?

The main challenges include the regulatory burden associated with new product approvals and potential supply chain disruptions due to the short half-life of Technetium-99m[3][4].

Sources

1. DRAXIMAGE DTPA - FDA Label[1].
2. DRAXIMAGE DTPA Kit - Health Canada[2].
3. Technetium-99m Market: Industry Analysis and Forecast 2030 - Maximize Market Research[3].
4. Technetium-99m Radiopharmaceuticals: Status and Trends - IAEA[4].